 |
|
|
| Poster session 2: Myeloma |
| Date: | Saturday, 14 June 2003 |
| Time: | 17:15-18:45 |
| Room: | |
| 17:15-18:45 |
0490 |
|
|
RESULTS OF TWO MULTICENTER PHASE II TRIALS USING THE PROTEASOME INHIBITOR, BORTEZOMIB IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (MM)
S. Jagannath, P. Richardson, B. Barlogie, J. Berenson, S. Singal, D. Siegel, D. Irwin, M. Schuster, V. Rajkumar, R. Alexanian, G. Srkalovic, S. Limentani, M. Alsina, R. Orlowski, D. Esseltine, K. Anderson (New York, United States of America)
| 17:15-18:45 |
0492 |
|
|
ANGIOGENESIS IN THE BONE MARROW OF PATIENTS WITH MULTIPLE MYELOMA BEFORE AND AFTER TREATMENT WITH THALIDOMIDE/VAD. A FOLLOW-UP HISTOLOGICAL AND IMMUNOHISTOCHEMICAL STUDY OF 15 CASES
C. Hadjileontis, V. Kaloutsi, M. Papaioannou, E. Hadjiharisi, K. Zervas, C. Papadimitriou (Thessaloniki, Greece)
| 17:15-18:45 |
0493 |
|
|
SERUM LEVELS OF MACROPHAGE INFLAMMATORY PROTEIN-1 ALPHA (MIP-1A) ARE CORRELATED WITH THE EXTENT OF BONE DISEASE AND SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA
E. Terpos, M. Politou, R. Szydlo, J.M. Goldman, J.F. Apperley, A. Rahemtulla (London, United Kingdom)
| 17:15-18:45 |
0494 |
|
|
THE UPDATED RESULTS OF AN OPEN, NON-COMPARATIVE, PILOT STUDY ON THE EMPLOYING OF HIGH DOSES OF EPOETIN ALFA IN THE TREATMENT OF MULTIPLE MYELOMA-RELATED ANEMIA
P. Niscola, L. Scaramucci, L. Menichelli, V. Bongarzoni, C. De Gregoris, M. Morucci, V. Tini, M. Montanaro (Montefiascone (viterbo), Italy)
| 17:15-18:45 |
0495 |
|
|
EXPRESSION OF THE CD117 ANTIGEN (C-KIT) ON MYELOMATOUS PLASMA CELLS AND ITS CLINICAL IMPLICATIONS
M. Kraj, R. Poglod, J. Kopec-Szlezak, U. Sokolowska, J. Wozniak, B. Kruk (Warsaw, Poland)
| 17:15-18:45 |
0496 |
|
|
OSTEOPROTEGERIN AND SOLUBLE RANKL SERUM LEVELS IN MULTIPLE MYELOMA PATIENTS
M. Kraj, P. Centkowski, B. Kruk (Warsaw, Poland)
| 17:15-18:45 |
0497 |
|
|
T(11;14) AND T(4;14) TRANSLOCATIONS CORRELATED WITH MATURE LYMPHOPLASMOCYTOID AND IMMATURE MORPHOLOGY, RESPECTIVELY, IN MULTIPLE MYELOMA (MM)
R. Garand, H. Avet-Loiseau, F. Accard, P. Moreau, J.L. Harousseau, R. Bataille (Nantes, France)
| 17:15-18:45 |
0498 |
|
|
BCL-2 AND MYELOMA: A PROSPECTIVE STUDY
B. Myers, N.H. Russell, D. Bradbury (Nottingham, United Kingdom)
| 17:15-18:45 |
0499 |
|
|
OPTIMIZATION OF THE RISK/BENEFIT RATIO OF THALIDOMIDE ADMINISTRATION IN PATIENTS WITH MULTIPLE MYELOMA (MM)
M. Offidani, M. Marconi, L. Corvatta, A. Olivieri, M. Catarini, A. Mele, M. Brunori, M. Candela, L. Malerba, D. Capelli, M. Montanari, S. Rupoli, P. Leoni (Ancona, Italy)
| 17:15-18:45 |
0500 |
|
|
GENETIC CHANGES BY COMPARATIVE GENOMIC HYBRIDIZATION IN SMOLDERING MULTIPLE MYELOMA (SMM). DIFFERENT PATTERN ACCORDING TO THE SMM TYPE (EVOLVING VS NON-EVOLVING)
L. Rosiñol, R. Queralt, A. Carrió, M. Aymerich, M. Rozman, J. Bladé, E. Campo, E. Montserrat (Barcelona, Spain)
| 17:15-18:45 |
0501 |
|
|
RESPONSE TO THALIDOMIDE IN MULTIPLE MYELOMA: IMPACT OF ANGIOGENIC FACTORS AND EXTRAMEDULLARY INVOLVEMENT
L. Rosiñol, J. Bladé, M.C. Cid, C. Segarra, M.T. Cibeira, X. Filella, M. Aymerich, M. Rozman, J. Esteve, E. Montserrat (Barcelona, Spain)
| 17:15-18:45 |
0502 |
|
|
A POLYMORPHISM IN ENDOSTATIN, AN ANGIOGENESIS INHIBITOR, IN MULTIPLE MYELOMA
M.M. Ortega, H. Nascimento, M.T. Teori, F.F. Costa, C.S.P. Lima (Campinas Sp, Brazil)
| 17:15-18:45 |
0503 |
|
|
SOCS-1 GENE METHYLATION IS FREQUENT BUT DOES NOT APPEAR TO HAVE PROGNOSTIC VALUE IN PATIENTS WITH MULTIPLE MYELOMA
S. Depil, D. Hétuin, G. Guillerm, X. Leleu, D. Wolowiec, F. Bauters, T. Facon, B. Quesnel (Lille, France)
| 17:15-18:45 |
0504 |
|
|
FINAL RESULTS FROM A PHASE I/II STUDY OF SU006668 IN PATIENTS (PTS) WITH MULTIPLE MYELOMA
J.D. Cavenagh, M. Kropff, W. Fiedler, C. Craddock, H. Einsele, H. Oakervee, L.K. Goff, S. Lanzalone, G. Massimini, P. Scigalla (London, United Kingdom)
| 17:15-18:45 |
0505 |
|
|
PLASMOBLASTIC MYELOMA OF THE SPINE:DIAGNOSTIC APPROACH AND CLINICAL OUTCOME
G. Luzi, A. Chierichini, B. Ronci, F. Monardo, M. Bartolini, P. Iacovino, M. Persiani, S. Nardelli, S. Esposito, L. Annino (Rome, Italy)
| 17:15-18:45 |
0506 |
|
|
PATIENTS WITH MULTIPLE MYELOMA AND PROLONGED SURVIVAL AFTER CONVENTIONAL CHEMOTHERAPY
S. Stankovic, N. Siljanovski, T. Smilevska, L. Hadzi-Pecova, S. Genadieva-Stavric, M. Pavkovic, L. Cevreska (Skopje, Macedonia)
| 17:15-18:45 |
0507 |
|
|
SYNDECAN 1 IN MULTIPLE MYELOMA: RELATIONSHIP TO CONVENTIONAL PROGNOSTIC FACTORS
S. Aref, T. Goda, M. El-Sherbiny (Mansoura, Egypt)
| 17:15-18:45 |
0508 |
|
|
LOW DOSE THALIDOMIDE IS AN EFFECTIVE THERAPY FOR RELAPS AFTER STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
M. Kees, Ch. Sillaber, J. Drach, J. Ackermann, H. Gisslinger (Vienna, Austria)
| 17:15-18:45 |
0509 |
|
|
ASSESSMENT OF THE IMMUNE CAPACITY OF MYELOMA PATIENTS POST AUTOLOGOUS STEM CELL TRANSPLANTATION: INFORMATION FOR PLANNING VACCINE-BASED IMMUNOTHERAPY
F.P. McNicholl, H. McCarthy, C.H. Ottensmeier, A.S. Duncombe, K.H. Orchard, A.G. Smith, F.K. Stevenson (Southampton, United Kingdom)
| 17:15-18:45 |
0510 |
|
|
ELEVATED SERUM LEVEL OF PROAGIOGENIC FACTORS: VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND MONOCYTE CHEMOTACTIC PROTEIN - 1 (MCP-1) IN PATIENTS WITH MULTIPLE MYELOMA
G. Mazur, L. Usnarska-Zubkiewicz, T. Wrobel, K. Kuliczkowski (Wroclaw, Poland)
| 17:15-18:45 |
0511 |
|
|
COMBINATION THERAPY FOR AL-AMYLOIDOSIS WITH THALIDOMIDE, CYCLOPHOSHAMIDE AND DEXAMETHASONE- PRELIMINARY RESULTS OF SFLCS (C-THAD)
B. Myers, N.H. Russell, J.F. Byrne, D. Mitchell (Nottingham, United Kingdom)
| 17:15-18:45 |
0512 |
|
|
THE EXPRESSION OF VLA-5 MOLECULE REFRECTS THE RESPONSIVENESS TO THE CHEMOTHERAPY IN MULTIPLE MYELOMA CASES
M. Noguchi, K. Nogi, C. Shimazu, H. Tashiro, S. Komaba, M. Goto, K. Kawasugi, N. Shirafuji (Tokyo, Japan)
| 17:15-18:45 |
0513 |
|
|
TO THE PROBLEM CONCERNING THE APPLICATION OF GLUCOCORTICOIDS AT A MULTIPLE MYELOMA
Y.M. Kuchma, O.A. Rukavitcin (Moscow, Russian Federation)
| 17:15-18:45 |
0514 |
|
|
HHV-8 VIRAL IL-6 HOMOLOGUE IS AS ACTIVE AS HUMAN IL-6 ON HUMAN MYELOMA CELLS
A. Guenther, F. Bakker, W. Baum, R. Burger, F. Neipel, M. Gramatzki (Erlangen, Germany)
| 17:15-18:45 |
0515 |
|
|
DETECTION OF MULTIPLE IGH GENE REARRANGEMENTS IN PATIENTS WITH MULTIPLE MYELOMA
E. Novella, E. Albiero, D. Domenico Madeo, F. Elice, I. Giaretta, F. Rodeghiero (Vicenza, Italy)
| 17:15-18:45 |
0516 |
|
|
THE ANTI MYELOMA EFFECT OF ERYTHROPOIETIN - REPORT ON PATIENTS SUPPORTED BY ANIMAL STUDIES
M. Mittelman, A. Zeidman, Z. Fradin, P. Kanter, O. Katz, D. Neumann (Petah-tikva, Israel)
| 17:15-18:45 |
0517 |
|
|
NON-FROZEN PERIPHERAL BLOOD STEM CELLS AUTOTRANSPLANTS IN MULTIPLE MYELOMA
M.I. Belkaid, A-M. Pequin, J.C. Saly, C. Ricard, B. Bourgeon, T. Henni (Saint Denis Cedex, Reunion)
| 17:15-18:45 |
0518 |
|
|
PRAME GENE EXPRESSION IN PATIENTS WITH MULTIPLE MYELOMA
V. Bebeshko, I.A. Kryachok, N.I. Bilous, I.V. Abramenko (Kiev, Ukraine)
| 17:15-18:45 |
0519 |
|
|
EX VIVO PROTON NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY (1H NMR) OF NATIVE MYELOMA CELLS. PRELIMINARY ASSESSMENT OF ITS POTENTIAL UTILITY TO QUANTIFY BONE MARROW INFILTRATION IN VIVO
A. Oriol, D. Valverde, A. Barberá, M. Cabañas, J.M. Ribera, C. Arús (Badalona, Spain)
| 17:15-18:45 |
0520 |
|
|
BORTEZOMIB (FORMER PS-341): ANTIMYELOMA EFFECT IS INDEPENDENT OF BCL-2 STATUS
E. Terpos, M. Politou, I. Lampert, L. Armstrong, E. Kanfer, J.F. Apperley, A. Rahemtulla (London, United Kingdom)
| 17:15-18:45 |
0521 |
|
|
VOLUME LOCALIZED IN VIVO PROTON MAGNETIC RESONANCE SPECTROSCOPY (MRS) OF THE SPINE IN MULTIPLE MYELOMA: VARIATION OF WATER-FAT RATIO IN PATIENTS RECEIVING CHEMOTHERAPY
A. Oriol, J. Capellades, D. Valverde, M. Cabañas, J.M. Ribera, C. Arús (Badalona, Spain)
| 17:15-18:45 |
0522 |
|
|
RESULTS OF MAINTENANCE THERAPY WITH INTERFERON ALPHA IN THE PATIENTS WITH MULTIPLE MYELOMA
H. Ionita, R. Mihaescu, A. Isac, L. Cheveresan, M. Iordache, I. Ionita, C. Cotoraci, M. Cheveresan, R. Martincu, M. Ionita (Timisoara, Romania)
| 17:15-18:45 |
0523 |
|
|
PRIMARY PLASMA CELL LEUKEMIA, REPORT OF 8 PATIENTS
H.G.Q. Garcia Quiroga, I. Castro, M. Fraga, J. Andrade, A. Costa, C. Granato, Mendonça, Candeias (Porto, Portugal)
| 17:15-18:45 |
0524 |
|
|
LONG-TERM FOLLOW UP OF MULTIPLE MYELOMA PATIENTS TREATED WITH CONVENTIONAL CHEMOTHERAPY
J. Bila, I. Elezovic, D. Tomin, M. Gotic, N. Suvajdzic, M. Sretenovic, V. Cemerikic, D. Boskovic (Belgrade, Yugoslavia)
| 17:15-18:45 |
0525 |
|
|
THALIDOMIDE IN THE TREATMENT OF RELAPSED/REFRACTORY MYELOMA
J. Bila, I. Elezovic, D. Tomin, M. Gotic, B. Mihaljevic, N. Suvajdzic, M. Sretenovic, V. Cemerikic, D. Boskovic (Belgrade, Yugoslavia)
| 17:15-18:45 |
0526 |
|
|
COSTS OF MULTIPLE MYELOMA AND ASSOCIATED SKELETAL-RELATED EVENTS IN THE NETHERLANDS
M.T. Groot, P.C. Huijgens, P.J. Wijermans, C.A. Groot (Rotterdam, The Netherlands)
| 17:15-18:45 |
0527 |
|
|
CYTOGENETIC ANALYSIS AND DNA CONTENT OF A SERIES OF 24 MULTIPLE MYELOMA PATIENTS
T. Mendonca, P. Lúcio, H. Alaiz, I. Dias, V. Oliveira, S. Oliveira, A. Santos, I. Santos, A. Parreira, M. Gomes da Silva (Lisboa, Portugal)
| 17:15-18:45 |
0528 |
|
|
PRELIMINARY FINDINGS IN A PHASE 1/2 STUDY OF TRISENOX(R) (ARSENIC TRIOXIDE) DOSED TWICE WEEKLY IN PATIENTS WITH ADVANCED MULTIPLE MYELOMA
J. Berenson, H. Yang, R. Vescio, R. Swift, K. Sadler, R. Ellison (Los Angeles Ca, United States of America)
| 17:15-18:45 |
0529 |
|
|
DEEP-VEIN THROMBOSIS IN MULTIPLE MYELOMA AFTER FIRST-LINE CHEMOTHERAPY WITHOUT THALIDOMIDE
A. Di Mario, E. Rossi, V. De Stefano (Rome, Italy)
| 17:15-18:45 |
0530 |
|
|
VACCINATION IN MULTIPLE MYELOMA PATIENTS: LACK OF RESPONSE IN ADVANCED AND REFRACTORY PATIENTS
N. Meuleman, I. Clement Corral, C. Dedobbeleer, I. Ahmad, D. Bron (Brussel, Belgium)
| 17:15-18:45 |
0531 |
|
|
TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA WITH THALIDOMIDE, DEXAMETHASONE AND CLARITHROMYCIN
N. Meuleman, C. Dedobbeleer, F. Djouba, I. Ahmad, I. Clement Corral, D. Bron (Brussel, Belgium)
| 17:15-18:45 |
0532 |
|
|
INTERLEUKIN-18 IN MULTIPLE MYELOMA PATIENTS: SERUM LEVELS IN RELATION TO RESPONSE TO TREATMENT AND SURVIVAL
F.H. Passam, K. Sfiridaki, C. Pappa, D. Liapi, E. Petreli, P. Roussou, D.S. Kyriakou, M.G. Alexandrakis (Heraklion Crete, Greece)
| 17:15-18:45 |
0533 |
|
|
THE EFFECT OF THALIDOMIDE AND DEXAMETHASONE TREATMENT ON THE LEVEL OF SERUM POLYCLONAL IMMUNOGLOBULINS IN PATIENTS WITH MULTIPLE MYELOMA
H. Ciepluch, W. Baran, W. Knopinska-Posluszny, A. Hellmann (Gdansk, Poland)
| 17:15-18:45 |
0534 |
|
|
SOLUBLE UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (SUPAR) AS AN INDEPENDENT FACTOR PREDICTING WORSE PROGNOSIS AND EXTRA BONE MARROW INVOLVEMENT IN MULTIPLE MYELOMA PATIENTS
G.M. Rigolin, A. Tieghi, M. Ciccone, L. Zenone Bragotti, F. Cavazzini, M. Della Porta, B. Castagnari, R. Carroccia, G. Guerra, A. Cuneo, G. Castoldi (Ferrara, Italy)
| 17:15-18:45 |
0535 |
|
|
INTERLEUKIN 6 (IL-6) AND SOLUBLE RECEPTOR FOR IL-6 (SIL-6R) AS A PROGNOSTIC FACTORS IN PATIENTS WITH MULTIPLE MYELOMA
G. Charlinski, J. Dwilewicz-Trojaczek, M. Paluszewska, M. Krol (Warsaw, Poland)
| 17:15-18:45 |
0536 |
|
|
EVIDENCE OF PLATELET ACTIVATION IN MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE
I. Kotsianidis, E. Spanoudakis, C. Tsatalas, D. Margaritis, D. Pantelidou, Z. Kartasis, M. Baka, G. Tripsianis, G. Bourikas (Alexandroupolis, Greece)
| 17:15-18:45 |
0537 |
|
|
PROLIFERATIVE ACTIVITY OF MYELOMA CELLS MEASURED WITH KI-67: CORRELATION WITH CLINICAL AND HISTOLOGICAL FEATURES
O. Markovic, D. Marisavljevic, V. Cemerikic, N. Suvajdzic, A. Bogdanovic, M. Perunicic, M. Colovic (Belgrade, Serbia)
| 17:15-18:45 |
0538 |
|
|
EXPRESSION OF CYCLIN D1 IN NEWLY DIAGNOSED MULTIPLE MYELOMA: BIOLOGICAL AND CLINICAL SIGNIFICANCE
O. Markovic, D. Marisavljevic, V. Cemerikic, M. Perunicic, D. Tomin, N. Suvajdzic, A. Bogdanovic, M. Colovic (Belgrade, Serbia)
| 17:15-18:45 |
0539 |
|
|
PATHOGENESIS OF RENAL FAILURE IN MULTIPLE MYELOMA
D. Badea, M. Badea, A. Genunche, C. Petrica (Craiova, Romania)
| 17:15-18:45 |
0540 |
|
|
LOW DOSE THALIDOMIDE AS A TREATMENT FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
S.S. Gan, S.C. Ng, A.K.H. Teh, K.Y. Goh, V.S Jaganathan (Kuala Lumpur, Malaysia)
| 17:15-18:45 |
0541 |
|
|
ARSENIC TRIOXIDE (TRISENOX®), ASCORBIC ACID (AA), AND DEXAMETHASONE (DEX) PULSES-TAD FOR RELAPSED REFRACTORY PROGRESSIVE MULTIPLE MYELOMA PATIENTS
M.A. Hussein, P. Elson, J. Reed, M. Kelly, L. Platt, M.R. Kovak, M.A. Karam, G. Srkalovic (Cleveland, United States of America)
| 17:15-18:45 |
0542 |
|
|
EFFECTIVE MANAGEMENT OF THE MULTIPLE MYELOMA-RELATED ANEMIA BY HIGH DOSES OF EPOETIN ALFA: THE UPDATED RESULTS OF AN OPEN AND NON COMPARATIVE STUDY
P. Niscola, L. Scaramucci, L. Menichelli, V. Bongarzoni, R. Ciafrino, C. De Gregoris, M. Morucci, V. Tini, M. Montanaro (Montefiascone (viterbo), Italy)
| 17:15-18:45 |
0543 |
|
|
THE PATTERN AND THE OUTCOME OF RELAPSED/REFRACTORY MULTIPLE MYELOMA IN PATIENTS ON SALVAGE TREATMENT WITH THALIDOMIDE, DEXAMETASONE AND ZOLENDRONATE
P. Niscola, L. Scaramucci, V. Bongarzoni, R. Ciafrino, C. De Gregoris, M. Morucci, V. Tini, M. Bibas, A. Ferrari, M. Montanaro (Montefiascone (viterbo), Italy)
| 17:15-18:45 |
0544 |
|
|
SIGNIFICANCE OF CYCLIN D1 OVEREXPRESSION IN MULTIPLE MYELOMA PATIENTS
G. Martinelli, S. Soverini, M. Cavo, C. Terragna, D. Ruggeri, N. Testoni, C. Cellini, A. De Vivo, M. Amabile, T. Grafone, P. Tosi, E. Zamagni, F. Bonifazi, D. Cangini, S. Tura, M. Baccarani (Bologna, Italy)
| 17:15-18:45 |
0545 |
|
|
THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE AND CYCLOPHOSPHAMIDE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
C.T. Caravita, A. Siniscalchi, M. Masi, M. Postorino, A. Franchi, S. Amadori (Rome, Italy)
| 17:15-18:45 |
0546 |
|
|
PREDICTORS OF LENGTH OF FIRST COMPLETE REMISSION IN NEW PATIENTS WITH SECRETORY MYELOMA
B. Sirohi, R. Powles, J. Mehta, S. Kulkarni, C. Horton, R. Saso, S. Singhal (Sutton, United Kingdom)
| 17:15-18:45 |
0547 |
|
|
10-YEAR SURVIVAL IN MYELOMA: A NEW ENDPOINT FOR TESTING POTENTIALLY CURATIVE STRATEGIES?
R. Powles, B. Sirohi, J. Mehta, S. Kulkarni, C. Horton, S. Singhal (Sutton, United Kingdom)
| 17:15-18:45 |
0548 |
|
|
DNA PLOIDY AND PROLIFERATIVE INDEX (S-PHASE) IN BONE MARROW PLASMA CELLS AND ITS INFLUENCE IN RESPONSE TO INDUCTION THERAPY AND OUTCOME IN MULTIPLE MYELOMA
C. Geraldes, P. Lopez, A. Paiva, R. Afonso, M. Vivan, A. Teixeira, F. Regateiro, F. Plácido (Coimbra, Portugal)
| 17:15-18:45 |
0549 |
|
|
DOXIL, VINCRISTINE, DECADRON AND THALIDOMIDE (DVD-T) FOR RELAPSED/ REFRACTORY MULTIPLE MYELOMA (RMM)
M.A. Hussein, P. Elson, E. Tso, M.A. Karam, J. Reed, R. Rodgers, M. Kelly, G. Srkalovic (Cleveland, United States of America)
| 17:15-18:45 |
0550 |
|
|
LONG LASTING REMISSION IN SOLITARY CNS PLASMOCYTOMA
A.V. Vidovic, B. Mihaljevic, D.A. Antic, V. Lazarevic, R. Jancic Nedeljkov, D.T. Tomin, D.B. Boskovic, M. Colovic (Belgrade, Serbia)
|